Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.39 |
| ▸ | PNMT | P11086 | 2/20 | 0.37 |
| ▸ | TKT | P29401 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403867 | 0.80 | KMT2A (0.39) | TKTCHRNB2CHRNA4TUBB4ATUBB | |
| SCHEMBL9269242 | 0.80 | CTRC (0.38) | TKTCHRNB2CHRNA4TUBB4ATUBB | |
| SCHEMBL555084 | 0.80 | NOS3 (0.54) | NOS3NOS1NOS2HTTGABRA1 | |
| SCHEMBL29421763 | 0.80 | KMT2A (0.39) | TKTCHRNB2CHRNA4TUBB4ATUBB | |
| SCHEMBL17051314 | 0.79 | KDM4E (0.39) | CHRNB2CHRNA4NOS3NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL1902299 | 0.78 | NOS3 (0.52) | NOS3NOS1NOS2GABRA1GABRB2 | |
| SCHEMBL16813060 | 0.78 | PDCD1LG2 (0.33) | CD274PDCD1LG2 | |
| Hydrochloric Acid SCHEMBL17442658 | 0.78 | NOS3 (0.52) | NOS3NOS1NOS2GABRA1GABRB2 | |
| SCHEMBL14011096 | 0.78 | CHRNB2 (0.33) | TKTCHRNB2CHRNA4TUBB4ATUBB | |
| SCHEMBL3510309 | 0.78 | CHRNB2 (0.33) | TKTCHRNB2CHRNA4TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| EP-2417120-B1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-2417120-B1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-102388032-B | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INT | 2015-01-14 | — | — | CN | disclosed |
| US-RE45323-E1 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-RE45323-E1 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-RE45323-E1 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| CN-102388032-A | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INT | 2012-03-21 | — | — | CN | disclosed |
| EP-2417120-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115836-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115836-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | CD274 981/4885PDCD1LG2 1821/4885PNMT 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.